These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7232826)

  • 61. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 64. Phase II evaluation of diaziquone in recurrent head and neck cancer.
    Kish JA; Ensley J; Al-Sarraf M
    Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
    [No Abstract]   [Full Text] [Related]  

  • 65. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
    Decker DA; Samson MK; Haas CD; Baker LH
    Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase II clinical evaluation of AZQ in renal cell carcinoma.
    Decker DA; Kish J; Al-Sarraf M; Goldfarb S
    Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunomodulating effects of BM 12.531 in animals and tolerance in man.
    Bicker U
    Cancer Treat Rep; 1978 Nov; 62(11):1987-96. PubMed ID: 728913
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia.
    Wodinsky I; Clement J; Swiniarski J; Skura A
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1677-80. PubMed ID: 536276
    [No Abstract]   [Full Text] [Related]  

  • 70. Phase II trial of diaziquone in advanced upper aerodigestive cancer.
    Creagan ET; Long HJ; Kvols LK; Edmonson JH; O'Fallon JR
    Cancer Treat Rep; 1985 Jan; 69(1):141. PubMed ID: 3967258
    [No Abstract]   [Full Text] [Related]  

  • 71. [Effect of the cytotoxic action preparation fotrin on the function of the adrenal cortex in the treatment of reticulodermia].
    Soloveĭ SN; Kalamkarian AA; Chumakov NN; Zavadskiĭ VN
    Vestn Dermatol Venerol; 1975 Dec; (12):8-11. PubMed ID: 1229676
    [No Abstract]   [Full Text] [Related]  

  • 72. Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.
    Khan AH; Driscoll JS
    J Med Chem; 1976 Feb; 19(2):313-7. PubMed ID: 1249812
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II clinical evaluation of AZQ in metastatic breast cancer.
    Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Results of the clinical study of a preparation of diiodobenzotef in malignant tumors].
    Karev NI; Garin AM; Blokhina NG; Pershin MP; Trapeznikova MF
    Klin Med (Mosk); 1975 May; 52(5):50-3. PubMed ID: 1133992
    [No Abstract]   [Full Text] [Related]  

  • 75. Photosensitization of leukemia L1210 cells with diaziquone.
    Kessel D; Thompson P
    Cancer Res; 1986 Nov; 46(11):5587-8. PubMed ID: 3756904
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
    Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
    Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
    [No Abstract]   [Full Text] [Related]  

  • 78. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
    [No Abstract]   [Full Text] [Related]  

  • 79. Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study.
    Shildt R; Stephens RL; Subramanian VP; Baker LH; Fletcher WS; O'Bryan RM; McCracken JD
    Cancer Treat Rep; 1985 Jun; 69(6):709-10. PubMed ID: 4016775
    [No Abstract]   [Full Text] [Related]  

  • 80. Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
    Chan C; Bartolucci A; Brenner D; Presant C; Davila E; Carpenter J; Greco FA; Clamon G; Moore J
    Cancer Treat Rep; 1986 Mar; 70(3):427-8. PubMed ID: 3456834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.